Body Mass Index Does Not Affect Suppression of Hyperandrogenism but Does Impact Carbohydrate Metabolism During Low-Dose Folate-Supplemented Ethinyl Estradiol / Drospirenone Oral Contraceptive Therapy in Women with Polycystic Ovary Syndrome

摘要

OBJECTIVE: To evaluate low-dose folate-supplemented ethinyl estradiol drospirenone (EE/DRSP) oral contraceptive (OC) therapy on clinical, hormonal, and cardiometabolic parameters in women with polycystic ovary syndrome (PCOS) stratified by body mass index (BMI).